Gideon M. Blumenthal

16.2k total citations · 6 hit papers
119 papers, 7.5k citations indexed

About

Gideon M. Blumenthal is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Gideon M. Blumenthal has authored 119 papers receiving a total of 7.5k indexed citations (citations by other indexed papers that have themselves been cited), including 77 papers in Oncology, 61 papers in Pulmonary and Respiratory Medicine and 33 papers in Cancer Research. Recurrent topics in Gideon M. Blumenthal's work include Lung Cancer Treatments and Mutations (44 papers), Cancer Immunotherapy and Biomarkers (31 papers) and Cancer Genomics and Diagnostics (26 papers). Gideon M. Blumenthal is often cited by papers focused on Lung Cancer Treatments and Mutations (44 papers), Cancer Immunotherapy and Biomarkers (31 papers) and Cancer Genomics and Diagnostics (26 papers). Gideon M. Blumenthal collaborates with scholars based in United States, Thailand and Switzerland. Gideon M. Blumenthal's co-authors include Richard Pazdur, Phillip A. Dennis, Patricia Keegan, M. Christine Hollander, Kun He, Dickran Kazandjian, Jaclyn LoPiccolo, Wendy B. Bernstein, Kirsten B. Goldberg and Sean Khozin and has published in prestigious journals such as Journal of Clinical Oncology, Nature reviews. Cancer and Blood.

In The Last Decade

Gideon M. Blumenthal

117 papers receiving 7.3k citations

Hit Papers

Targeting the PI3K/Akt/mTOR pathway: Effective combinatio... 2008 2026 2014 2020 2008 2011 2016 2016 2018 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
    2008 656 citations Gideon M. Blumenthal et al. profile →
  2. PTEN loss in the continuum of common cancers, rare syndromes and mouse models
    2011 631 citations Gideon M. Blumenthal et al. profile →
  3. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy
    2016 337 citations Dickran Kazandjian, Gideon M. Blumenthal et al. The Oncologist profile →
  4. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1
    2016 285 citations Gideon M. Blumenthal, Xiaoping Jiang et al. The Oncologist profile →
  5. FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia
    2018 252 citations Aviva C. Krauss, Xin Gao et al. Clinical Cancer Research profile →
  6. PTEN hamartoma tumor syndromes
    2008 205 citations Gideon M. Blumenthal et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gideon M. Blumenthal United States 47 4.0k 2.6k 2.4k 1.3k 926 119 7.5k
Rajeshwari Sridhara United States 53 4.8k 1.2× 2.9k 1.1× 3.0k 1.3× 1.3k 1.0× 788 0.9× 137 9.3k
Christophe Le Tourneau France 46 4.9k 1.2× 2.3k 0.9× 2.1k 0.9× 1.6k 1.2× 1.3k 1.4× 335 8.7k
Patricia Keegan United States 54 5.0k 1.2× 3.1k 1.2× 2.1k 0.9× 1.6k 1.2× 1.3k 1.4× 140 9.3k
Elisabeth I. Heath United States 48 3.1k 0.8× 3.2k 1.3× 3.2k 1.3× 1.5k 1.2× 663 0.7× 342 8.5k
Shivaani Kummar United States 47 3.5k 0.9× 1.5k 0.6× 3.3k 1.4× 1.3k 1.0× 820 0.9× 296 7.0k
S. Percy Ivy United States 43 3.6k 0.9× 1.3k 0.5× 4.1k 1.7× 1.3k 1.0× 612 0.7× 189 7.9k
Matthew D. Galsky United States 55 5.6k 1.4× 3.8k 1.5× 3.3k 1.4× 1.6k 1.2× 1.2k 1.2× 393 13.2k
William T. Barry United States 47 4.3k 1.1× 1.6k 0.6× 2.1k 0.9× 2.4k 1.8× 569 0.6× 191 8.4k
Alan B. Sandler United States 44 4.5k 1.1× 3.7k 1.4× 2.4k 1.0× 1.0k 0.8× 638 0.7× 109 7.5k
Shenghui Tang United States 39 2.9k 0.7× 1.8k 0.7× 1.2k 0.5× 855 0.6× 590 0.6× 116 5.3k

Countries citing papers authored by Gideon M. Blumenthal

Since Specialization
Citations

This map shows the geographic impact of Gideon M. Blumenthal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gideon M. Blumenthal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gideon M. Blumenthal more than expected).

Fields of papers citing papers by Gideon M. Blumenthal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gideon M. Blumenthal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gideon M. Blumenthal. The network helps show where Gideon M. Blumenthal may publish in the future.

Co-authorship network of co-authors of Gideon M. Blumenthal

This figure shows the co-authorship network connecting the top 25 collaborators of Gideon M. Blumenthal. A scholar is included among the top collaborators of Gideon M. Blumenthal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gideon M. Blumenthal. Gideon M. Blumenthal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Herbst, Roy S., Gideon M. Blumenthal, Samir N. Khleif, et al.. (2024). Optimizing public-private partnerships to support clinical cancer research. JNCI Journal of the National Cancer Institute. 117(7). 1305–1310. 1 indexed citations
3.
Singh, Harpreet, Gideon M. Blumenthal, & Richard Pazdur. (2020). Approvals in 2019: international review and a new agnostic molecular entity. Nature Reviews Clinical Oncology. 17(3). 130–131. 7 indexed citations
4.
Forde, Patrick M., P. Bonomi, Alice T. Shaw, et al.. (2020). Expanding Access to Lung Cancer Clinical Trials by Reducing the Use of Restrictive Exclusion Criteria: Perspectives of a Multistakeholder Working Group. Clinical Lung Cancer. 21(4). 295–307. 10 indexed citations
5.
Kasamon, Yvette L., Haiyan Chen, R. Angelo de Claro, et al.. (2019). FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome. Clinical Cancer Research. 25(24). 7275–7280. 51 indexed citations
6.
Przepiorka, Donna, Lola Luo, Sriram Subramaniam, et al.. (2019). FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease. The Oncologist. 25(2). e328–e334. 91 indexed citations
7.
Jen, Emily Y., Xin Gao, Liang Li, et al.. (2019). FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm. Clinical Cancer Research. 26(3). 532–536. 65 indexed citations
8.
Sissung, Tristan M., Arun Rajan, Gideon M. Blumenthal, et al.. (2019). Reproducibility of pharmacogenetics findings for paclitaxel in a heterogeneous population of patients with lung cancer. PLoS ONE. 14(2). e0212097–e0212097. 7 indexed citations
9.
Gao, Jennifer, Joyce Cheng, Erik Bloomquist, et al.. (2019). CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. The Lancet Oncology. 21(2). 250–260. 194 indexed citations
10.
Krauss, Aviva C., Xin Gao, Liang Li, et al.. (2018). FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia. Clinical Cancer Research. 25(9). 2685–2690. 252 indexed citations breakdown →
11.
Odogwu, Lauretta, Luckson Mathieu, Gideon M. Blumenthal, et al.. (2018). FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations. The Oncologist. 23(6). 740–745. 166 indexed citations
12.
Beaver, Julia A., Maitreyee Hazarika, Flora Mulkey, et al.. (2018). Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis. The Lancet Oncology. 19(2). 229–239. 112 indexed citations
13.
Bonomi, Philip, Gideon M. Blumenthal, Andrea Stern Ferris, et al.. (2018). Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility Criteria. Journal of Thoracic Oncology. 13(6). 748–751. 10 indexed citations
14.
Marur, Shanthi, Harpreet Singh, Pallavi S. Mishra‐Kalyani, et al.. (2018). FDA analyses of survival in older adults with metastatic non–small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies. Seminars in Oncology. 45(4). 220–225. 66 indexed citations
15.
Odogwu, Lauretta, Luckson Mathieu, Kirsten B. Goldberg, et al.. (2017). FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation. The Oncologist. 23(3). 353–359. 49 indexed citations
16.
McCoach, Caroline E., Gideon M. Blumenthal, Adrian Myers, et al.. (2017). Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy. Annals of Oncology. 28(11). 2707–2714. 63 indexed citations
17.
Blumenthal, Gideon M. & Richard Pazdur. (2017). Approvals in 2016: the march of the checkpoint inhibitors. Nature Reviews Clinical Oncology. 14(3). 131–132. 13 indexed citations
18.
Beaver, Julia A., Abraham Tzou, Gideon M. Blumenthal, et al.. (2016). An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies. Clinical Cancer Research. 23(6). 1368–1372. 26 indexed citations
19.
Waqar, Saiama N., Philip Bonomi, Ramaswamy Govindan, et al.. (2016). Clinician Perspectives on Current Issues in Lung Cancer Drug Development. Journal of Thoracic Oncology. 11(9). 1387–1396. 8 indexed citations
20.
Pignatti, Francesco, Bertil Jönsson, Gideon M. Blumenthal, & Robert Justice. (2014). Assessment of benefits and risks in development of targeted therapies for cancer — The view of regulatory authorities. Molecular Oncology. 9(5). 1034–1041. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rajeshwari Sridhara Breakdown of academic impact, for papers by Christophe Le Tourneau Breakdown of academic impact, for papers by Patricia Keegan Breakdown of academic impact, for papers by Elisabeth I. Heath Breakdown of academic impact, for papers by Shivaani Kummar Breakdown of academic impact, for papers by S. Percy Ivy Breakdown of academic impact, for papers by Matthew D. Galsky Breakdown of academic impact, for papers by William T. Barry Breakdown of academic impact, for papers by Alan B. Sandler Breakdown of academic impact, for papers by Shenghui Tang
Rankless by CCL
2026